GSTM1 and chronic kidney disease: This approval granted by the National Medical Products Administration is primally supported by Phase 3 clinical trial studies conducted in China and Japan, which reported the efficacy of Roxadustat in CKD patients on peritoneal dialysis and hemodialysis, and in non-dialysis-dependent chronic kidney disease patients by a statistically significant improvement in hemoglobin (Hb) levels [12].